Evidence map›Paper›PMID 37306500›Full record

ArticleOncotarget2023

ERβ as a mediator of estrogen signaling in inflammatory breast cancer.

Harika Nagandla, Christoforos Thomas

Open access · diamondAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Harika Nagandla
Christoforos Thomas

Funding

Exploring the role of estrogen receptor beta in progression and metastasis ofInflammatory breast cancerR01CA237200 · NCI · UNIVERSITY OF PENNSYLVANIA · PI THOMAS, CHRISTOFOROS · 2020 to 2024
$1.8M
Exploring the role of ER Beta in disease penetrance in individuals with Li-Fraumeni syndromeR21CA267386 · NCI · UNIVERSITY OF PENNSYLVANIA · PI THOMAS, CHRISTOFOROS · 2022 to 2023
$395k
NCI NIH HHS R01 CA237200NCI NIH HHS R21 CA267386
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Estrogen Receptor betaInflammatory Breast NeoplasmsHumansEstrogen Receptor betaactin based cell migrationERβIBCinflammatory breast cancermetastasis

Identifiers

PMID37306500
PMCPMC10259261
OpenAlexW4380291598

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.